Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.43 - $13.43 $459 - $4,311
321 Added 1.12%
28,881 $46,000
Q3 2022

Nov 14, 2022

SELL
$2.53 - $13.17 $129,222 - $672,670
-51,076 Reduced 64.14%
28,560 $264,000

Others Institutions Holding NERV

About Minerva Neurosciences, Inc.


  • Ticker NERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,340,190
  • Market Cap $12.2M
  • Description
  • Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...
More about NERV
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.